CTOR (Citius Oncology) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 05, 2026)


CTOR Citius Oncology Inc CTOR
10 GF Score
Price $0.68
! 2 Warning Signs
View Full Analysis

What is Citius Oncology 5-Year Yield-on-Cost %?

Citius Oncology CTOR -2.10% 10 5-Year Yield-on-Cost % is 0.00 as of Jul. 05, 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 517 Drug Manufacturers companies, Citius Oncology ranks worse than 193423.4% on this metric.

Citius Oncology's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Citius Oncology's 5-Year Yield-on-Cost % or its related term are showing as below:



CTOR's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.34
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Citius Oncology  (NAS:CTOR) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Citius Oncology 5-Year Yield-on-Cost % Related Terms


CTOR vs INCR, TLPH, ETST: 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Citius Oncology 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Citius Oncology's 5-Year Yield-on-Cost % falls into.


CTOR
10GF Score
Citius Oncology Inc CTOR
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citius Oncology 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Citius Oncology is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Citius Oncology (CTOR) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 05, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Citius Oncology and its competitors. According to the industry distribution chart, Citius Oncology ranks #999999 out of 517 companies in the Drug Manufacturers industry.
Is Citius Oncology's 5-Year Yield-on-Cost % too high?
Citius Oncology's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Citius Oncology ranks #999999 out of 517 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's 5-Year Yield-on-Cost % compare to INCR and TLPH?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #999999 out of 517 companies for 5-Year Yield-on-Cost %. This places Citius Oncology in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.34, based on 517 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Citius Oncology and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Oncology's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Citius Oncology (CTOR), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Oncology Business Description

Address 11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score

Get the complete analysis for CTOR

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.68
Price